The present invention describes a method for treating, removing or preventing a bacterial infection, which method comprises administering to a human suffering, suspected of suffering or at risk of suffering from
Staphylococcus aureus (S. aureus) infection, a
Streptococcus infection,
Escherichia coli (E. coli) infection,
Pseudomonas aeruginosa (P. aeruginosa) infection,
Acinetobacter baumannii (A. baumannii) infection,
Enterococcus faecium (E. faecium) infection and / or
Clostridium difficile (C. difficile) infection, an effective amount of human
polyclonal antibodies affinity purified from a
human blood sample with an antigenic preparation comprising cellular and / or secreted
antigen(s) from bacterial cells selected from S. aureus, a
Streptococcus, E. coli, P. aeruginosa, A. baumannii, E. faecium, C. difficile or a combination thereof, and optionally, wherein said affinity purified human
polyclonal antibodies are purified (e.g., as made more concentrated as compared to the starting or unpurified material) relative to the same human
polyclonal antibodies in the unpurified or non-affinity-purified
human blood sample, e.g., intravenous immunoglobulin (IVIG) sample, and / or also optionally, wherein said affinity purified human polyclonal antibodies are specific for the bacterial antigens used in the affinity purification, and / or further optionally wherein the affinity purified human polyclonal antibodies are substantially free of human antibodies that specifically bind to non-bacterial antigens in the
human blood sample. Pharmaceutical compositions for treating bacterial infections, comprising an effective amount of human polyclonal antibodies affinity purified from a human blood sample with an antigenic preparation comprising cellular and / or secreted
antigen(s) from S. aureus,
Streptococcus, E. coli, P. aeruginosa, A. baumannii, E. faecium, C. difficile or a combination thereof, are also provided.